Palopegteriparatide not checked
FollowEvery change as it happens, and a Monday email
Trials
4 active
5 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- Parathyroid Hormone Analog FDA class
- How it’s given
- “Palopegteriparatide is administered as separate SC injection in a prefilled, single-patient use pen. Treatment duration 78 weeks.”In the company’s words, NCT07081997 on ClinicalTrials.gov
- Tested for
- Hypoparathyroidism (2 trials), Endocrine System Diseases, Parathyroid Diseases
- Main trialPhase 3
- “This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.”In the company’s words, NCT07081997 on ClinicalTrials.gov
- Other names
- Yorvipath
Other drugs for Hypoparathyroidism
- CanvuparatideMBX Biosciences · Phase 3
- EncaleretCalcilytix Therapeutics, Inc., a BridgeBio company · Phase 3
- EneboparatideAlexion Pharmaceuticals, Inc. · Phase 3
- AMOR-1Amorphical Ltd. · Phase 2
- EXT608Extend Biosciences Inc. · Phase 2
Coming up2
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2027 | A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism | |
| Phase 3Recruiting | Aug 2027 | A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism | |
| Phase 2Ended | not given | PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism | |
| Phase 3Authorised | not given | PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism | |
| Phase 4Authorised | not given | Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026